Coblopasvir

Last updated

Coblopasvir
Coblopasvir.svg
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • Methyl N-[(2S)-1-[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C41H50N8O8
Molar mass 782.899 g·mol−1
  • InChI=InChI=1S/C41H50N8O8/c1-22(2)32(46-40(52)54-5)38(50)48-17-7-9-30(48)36-42-19-28(44-36)25-13-11-24(12-14-25)26-15-16-27(35-34(26)56-21-57-35)29-20-43-37(45-29)31-10-8-18-49(31)39(51)33(23(3)4)47-41(53)55-6/h11-16,19-20,22-23,30-33H,7-10,17-18,21H2,1-6H3,(H,42,44)(H,43,45)(H,46,52)(H,47,53)/t30-,31-,32-,33-/m0/s1
  • Key:JBYJTCVXUMWTJJ-YRCZKMHPSA-N

Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C. [1] It is a pan-genotypic inhibitor of HCV nonstructural protein 5A. [2]

In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis. [2]

References

  1. ↑ Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, et al. (January 2020). "Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis". Journal of Viral Hepatitis. 27 (1): 45–51. doi:10.1111/jvh.13208. PMID   31520460.
  2. 1 2 Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, et al. (November 2020). "Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial". Liver International. 40 (11): 2685–2693. doi:10.1111/liv.14633. PMC   7702130 . PMID   33047868.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.